Hoe bouw je IL-1-remmers af bij recidiverende pericarditis? Strategieën voor afbouw en staken

<p>Interleukin-1 (IL-1) blockers were first introduced into clinical practice approximately 15 years ago for the treatment of patients with glucocorticoid-dependent and colchicine-resistant (GD-CR) recurrent pericarditis. This marked a significant advancement that has radically changed the clinical landscape for this subgroup of patients.</p> <p>GD-CR affects approximately 5%&ndash;10% of patients with recurrent pericarditis.<cross-ref type="bib" refid="R1">1</cross-ref> Notably, the disease duration in these challenging cases may exceed 3 years.<cross-ref type="bib" refid="R2">2</cross-ref> Until recently, therapeutic options for this subgroup were limited and included glucocorticoids, colchicine, non-steroidal anti-inflammatory drugs (often combined as triple therapy) and conventional immunosuppressants for refractory cases.<cross-ref type="bib" refid="R3">3</cross-ref></p> <p>The paradox of recurrent pericarditis lies in the fact that its challenges do not exclusively stem from the